Multaq
(Dronedarone)ApprovedSmall molecule
SanofiDronedarone is used to help maintain a normal heart rhythm in patients with atrial fibrillation, a condition where the heart beats irregularly. It helps reduce the risk of hospitalizations related to this heart condition.[2] Multaq is currently approved and in use across 4 indications[4].[1]
Multaq is one of 80 small molecule programs targeting Atrial Fibrillation. It is currently in Approved.
4
Indications
27
Total Trials
1
Active Trials
79
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
137 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Multaq
SanofiApproved
Calquence
AstraZenecaPreclinical
Rituxan
RochePreclinical
Coumadin
AAbbott
Preclinical
Brukinsa
BBeOne Medicines
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation19 trials
Show 16 more trials
Paroxysmal atrial fibrillation3 trials
Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation
Unknown status·—·Phase 4·NCT01070667·50 enrolled
Cardioversion2 trials
Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus Rhythm
Unknown status·—·N/A·NCT01266681·100 enrolled
Congestive Heart Failure1 trial
Regulatory
FDA Approval Timeline[5]
Jul 1, 2009
MULTAQ
NDA NDA022425
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Multaq drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Dronedarone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Multaq. U.S. Food & Drug Administration.
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sodium Channel Alpha Subunit Blocker; Voltage-Gated L-Type Calcium Channel Blocker; Inward Rectifier Potassium Channel 2 Blocker; Potassium/sodium Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 4 Blocker[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company